In this episode, we review key updates from the 2025 American Thyroid Association guidelines on surveillance and radioactive iodine management for adult patients with differentiated thyroid cancer. • Surveillance: Ultrasound as first line follow up; 6 to12 month intervals; FNA for nodes ≥10 mm; CT or PET for rising thyroglobulin without visible disease • Radioactive Iodine: Not routine in low risk; recommended for high risk and metastatic cases; role in oncocytic thyroid carcinoma still uncertain • Preparation for RAI Therapy: Recombinant TSH preferred; TSH goal greater than 30 mIU/L; low iodine diet before treatment • Imaging: Pre and post therapy scans are essential• Safety: Oral and written radiation precautions for patients and families • Adverse Effects: Salivary gland dysfunction, xerostomia, and lacrimal duct problems, with hydration and preventive dental care recommended • Takeaway: Ultrasound and thyroglobulin trends guide surveillance, RAI therapy should be tailored to patient risk, and careful preparation along with safety measures are critical for long term management

Ver todos los episodios